Skip to main content
Top
Published in:

26-07-2023 | Review Article

A Clinical Guide to the Management of Intraductal Papillary Mucinous Neoplasms: the Need for a More Graded Approach in Clinical Decision-making

Authors: Zhi Ven Fong, Yasmin G. Hernandez-Barco, Carlos Fernández-del Castillo

Published in: Journal of Gastrointestinal Surgery | Issue 9/2023

Login to get access

Abstract

Intraductal papillary mucinous neoplasms (IPMNs) have become a very common diagnosis and represent a spectrum of disease that ranges from benign to malignant lesions. Presently, clinical and radiographic features are used to predict the presence of high-grade dysplasia and invasive cancer to inform treatment decisions of whether to pursuit surgical resection or continued surveillance. However, the natural history of IPMNs is still not completely understood, with guidelines from different societies providing contradictory recommendations. This underscores the challenge in balancing the risk of missing cancer with long-term surveillance and the morbidity associated with surgical resection. In this review, we aim to reconcile the differences in the guidelines’ recommendations and provide a clinical framework to the management of IPMNs with hopes of adding clarity to how treatment decisions should be made. We also highlight recent advances made in the field and future efforts that can minimize rates of missing cancer while also reducing the number of unnecessary operations.
Literature
2.
go back to reference Winter JM, Cameron JL, Lillemoe KD, et al. Periampullary and pancreatic incidentaloma: a single institution’s experience with an increasingly common diagnosis. Ann Surg. 2006;243:673–80; discussion 680–3. Winter JM, Cameron JL, Lillemoe KD, et al. Periampullary and pancreatic incidentaloma: a single institution’s experience with an increasingly common diagnosis. Ann Surg. 2006;243:673–80; discussion 680–3.
3.
go back to reference Sachs T, Pratt WB, Callery MP, et al. The incidental asymptomatic pancreatic lesion: nuisance or threat? J Gastrointest Surg. 2009;13:405–415.PubMedCrossRef Sachs T, Pratt WB, Callery MP, et al. The incidental asymptomatic pancreatic lesion: nuisance or threat? J Gastrointest Surg. 2009;13:405–415.PubMedCrossRef
4.
go back to reference Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006;10:1199–210; discussion 1210–1. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006;10:1199–210; discussion 1210–1.
5.
go back to reference Fong ZV, Alvino DM, Castillo CF-D, et al. Health-related quality of life and functional outcomes in 5-year survivors after pancreaticoduodenectomy. Ann Surg. 2017;266:685–692. Fong ZV, Alvino DM, Castillo CF-D, et al. Health-related quality of life and functional outcomes in 5-year survivors after pancreaticoduodenectomy. Ann Surg. 2017;266:685–692.
7.
go back to reference Morales-Oyarvide V, Mino-Kenudson M, Ferrone CR, et al. Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. Pancreatology. 2017;17:920–926.PubMedCrossRef Morales-Oyarvide V, Mino-Kenudson M, Ferrone CR, et al. Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. Pancreatology. 2017;17:920–926.PubMedCrossRef
8.
go back to reference Nehra D, Oyarvide VM, Mino-Kenudson M, et al. Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter? Pancreatology. 2012;12:358–363.PubMedCrossRef Nehra D, Oyarvide VM, Mino-Kenudson M, et al. Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter? Pancreatology. 2012;12:358–363.PubMedCrossRef
9.
go back to reference Ciprani D, Morales-Oyarvide V, Qadan M, et al. An elevated CA 19-9 is associated with invasive cancer and worse survival in IPMN. Pancreatology. 2020;20:729–735.PubMedCrossRef Ciprani D, Morales-Oyarvide V, Qadan M, et al. An elevated CA 19-9 is associated with invasive cancer and worse survival in IPMN. Pancreatology. 2020;20:729–735.PubMedCrossRef
10.
go back to reference Narimatsu H, Iwasaki H, Nakayama F, et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 1998;58:512–518.PubMed Narimatsu H, Iwasaki H, Nakayama F, et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 1998;58:512–518.PubMed
11.
go back to reference Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501–5503.PubMed Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501–5503.PubMed
13.
go back to reference Marchegiani G, Mino-Kenudson M, Sahora K, et al. IPMN involving the main pancreatic duct. Ann Surg. 2015;261:976–983.PubMedCrossRef Marchegiani G, Mino-Kenudson M, Sahora K, et al. IPMN involving the main pancreatic duct. Ann Surg. 2015;261:976–983.PubMedCrossRef
14.
go back to reference Sugiyama M, Izumisato Y, Abe N, et al. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg. 2003;90:1244–1249.PubMedCrossRef Sugiyama M, Izumisato Y, Abe N, et al. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg. 2003;90:1244–1249.PubMedCrossRef
15.
go back to reference Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol. 2000;24:1372–1377.PubMedCrossRef Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol. 2000;24:1372–1377.PubMedCrossRef
16.
go back to reference Waters JA, Schmidt CM, Pinchot JW, et al. CT vs MRCP: optimal classification of IPMN type and extent. J Gastrointest Surg. 2008;12:101–109.PubMedCrossRef Waters JA, Schmidt CM, Pinchot JW, et al. CT vs MRCP: optimal classification of IPMN type and extent. J Gastrointest Surg. 2008;12:101–109.PubMedCrossRef
17.
go back to reference Kang H-J, Lee JM, Joo I, et al. Assessment of malignant potential in intraductal papillary mucinous neoplasms of the pancreas: Comparison between multidetector CT and MR imaging with MR cholangiopancreatography. Radiology. 2016;279:128–139.PubMedCrossRef Kang H-J, Lee JM, Joo I, et al. Assessment of malignant potential in intraductal papillary mucinous neoplasms of the pancreas: Comparison between multidetector CT and MR imaging with MR cholangiopancreatography. Radiology. 2016;279:128–139.PubMedCrossRef
18.
go back to reference Kim KW, Park SH, Pyo J, et al. Imaging features to distinguish malignant and benign branch-duct type intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Ann Surg. 2014;259:72–81.PubMedCrossRef Kim KW, Park SH, Pyo J, et al. Imaging features to distinguish malignant and benign branch-duct type intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Ann Surg. 2014;259:72–81.PubMedCrossRef
19.
go back to reference Harima H, Kaino S, Shinoda S, et al. Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrast-enhanced endoscopic ultrasonography. World J Gastroenterol. 2015;21:6252–6260.PubMedPubMedCentralCrossRef Harima H, Kaino S, Shinoda S, et al. Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrast-enhanced endoscopic ultrasonography. World J Gastroenterol. 2015;21:6252–6260.PubMedPubMedCentralCrossRef
20.
go back to reference Yamashita Y, Ueda K, Itonaga M, et al. Usefulness of contrast-enhanced endoscopic sonography for discriminating mural nodules from mucous clots in intraductal papillary mucinous neoplasms: a single-center prospective study. J Ultrasound Med. 2013;32:61–68.PubMedCrossRef Yamashita Y, Ueda K, Itonaga M, et al. Usefulness of contrast-enhanced endoscopic sonography for discriminating mural nodules from mucous clots in intraductal papillary mucinous neoplasms: a single-center prospective study. J Ultrasound Med. 2013;32:61–68.PubMedCrossRef
21.
go back to reference Rodriguez JR, Salvia R, Crippa S, et al. Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology. 2007;133:72–9; quiz 309–10. Rodriguez JR, Salvia R, Crippa S, et al. Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology. 2007;133:72–9; quiz 309–10.
22.
go back to reference Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126:1330–1336.PubMedCrossRef Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126:1330–1336.PubMedCrossRef
23.
go back to reference Cizginer S, Turner BG, Bilge AR, et al. Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas. 2011;40:1024–1028.PubMedCrossRef Cizginer S, Turner BG, Bilge AR, et al. Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas. 2011;40:1024–1028.PubMedCrossRef
24.
go back to reference Smith ZL, Satyavada S, Simons-Linares R, et al. Intracystic glucose and carcinoembryonic antigen in differentiating histologically confirmed pancreatic mucinous neoplastic cysts. Am J Gastroenterol. 2022;117:478–485.PubMedCrossRef Smith ZL, Satyavada S, Simons-Linares R, et al. Intracystic glucose and carcinoembryonic antigen in differentiating histologically confirmed pancreatic mucinous neoplastic cysts. Am J Gastroenterol. 2022;117:478–485.PubMedCrossRef
25.
go back to reference Pitman MB, Genevay M, Yaeger K, et al. High-grade atypical epithelial cells in pancreatic mucinous cysts are a more accurate predictor of malignancy than “positive” cytology. Cancer Cytopathol. 2010;118:434–440.PubMedCrossRef Pitman MB, Genevay M, Yaeger K, et al. High-grade atypical epithelial cells in pancreatic mucinous cysts are a more accurate predictor of malignancy than “positive” cytology. Cancer Cytopathol. 2010;118:434–440.PubMedCrossRef
26.
go back to reference Genevay M, Mino-Kenudson M, Yaeger K, et al. Cytology adds value to imaging studies for risk assessment of malignancy in pancreatic mucinous cysts. Ann Surg. 2011;254:977–983.PubMedCrossRef Genevay M, Mino-Kenudson M, Yaeger K, et al. Cytology adds value to imaging studies for risk assessment of malignancy in pancreatic mucinous cysts. Ann Surg. 2011;254:977–983.PubMedCrossRef
27.
go back to reference Lee J-H, Kim Y, Choi J-W, et al. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Springerplus. 2016;5:1172.PubMedPubMedCentralCrossRef Lee J-H, Kim Y, Choi J-W, et al. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Springerplus. 2016;5:1172.PubMedPubMedCentralCrossRef
28.
go back to reference Springer S, Wang Y, Dal Molin M, et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology. 2015;149:1501–1510.PubMedCrossRef Springer S, Wang Y, Dal Molin M, et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology. 2015;149:1501–1510.PubMedCrossRef
29.
go back to reference Hao S, Takahashi C, Snyder RA, et al. Stratifying intraductal papillary mucinous neoplasms by cyst fluid analysis: Present and future. Int J Mol Sci. 2020;21:1147.PubMedPubMedCentralCrossRef Hao S, Takahashi C, Snyder RA, et al. Stratifying intraductal papillary mucinous neoplasms by cyst fluid analysis: Present and future. Int J Mol Sci. 2020;21:1147.PubMedPubMedCentralCrossRef
31.
go back to reference Khalid A, Zahid M, Finkelstein SD, et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc. 2009;69:1095–1102.PubMedCrossRef Khalid A, Zahid M, Finkelstein SD, et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc. 2009;69:1095–1102.PubMedCrossRef
32.
go back to reference Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32.PubMedCrossRef Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32.PubMedCrossRef
33.
go back to reference Tang RS, Weinberg B, Dawson DW, et al. Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol. 2008;6:815–9; quiz 719. Tang RS, Weinberg B, Dawson DW, et al. Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol. 2008;6:815–9; quiz 719.
34.
go back to reference Cauley CE, Waters JA, Dumas RP, et al. Outcomes of primary surveillance for intraductal papillary mucinous neoplasm. J Gastrointest Surg. 2012;16:258–67; discussion 266. Cauley CE, Waters JA, Dumas RP, et al. Outcomes of primary surveillance for intraductal papillary mucinous neoplasm. J Gastrointest Surg. 2012;16:258–67; discussion 266.
35.
go back to reference Nagai K, Doi R, Ito T, et al. Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg. 2009;16:353–358.PubMedCrossRef Nagai K, Doi R, Ito T, et al. Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg. 2009;16:353–358.PubMedCrossRef
36.
go back to reference Hoffman RL, Gates JL, Kochman ML, et al. Analysis of cyst size and tumor markers in the management of pancreatic cysts: support for the original Sendai criteria. J Am Coll Surg. 2015;220:1087–1095.PubMedCrossRef Hoffman RL, Gates JL, Kochman ML, et al. Analysis of cyst size and tumor markers in the management of pancreatic cysts: support for the original Sendai criteria. J Am Coll Surg. 2015;220:1087–1095.PubMedCrossRef
37.
go back to reference Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–197.PubMedCrossRef Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–197.PubMedCrossRef
38.
go back to reference Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17:738–753.PubMedCrossRef Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17:738–753.PubMedCrossRef
39.
go back to reference Sahora K, Mino-Kenudson M, Brugge W, et al. Branch duct intraductal papillary mucinous neoplasms. Ann Surg. 2013;258:466–475.PubMedCrossRef Sahora K, Mino-Kenudson M, Brugge W, et al. Branch duct intraductal papillary mucinous neoplasms. Ann Surg. 2013;258:466–475.PubMedCrossRef
40.
go back to reference Vege SS, Ziring B, Jain R, et al. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:819–22; quize12–3. Vege SS, Ziring B, Jain R, et al. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:819–22; quize12–3.
41.
go back to reference Pergolini I, Sahora K, Ferrone CR, et al. Long-term risk of pancreatic malignancy in patients with branch duct intraductal papillary mucinous neoplasm in a referral center. Gastroenterology. 2017;153:1284-1294.e1.PubMedCrossRef Pergolini I, Sahora K, Ferrone CR, et al. Long-term risk of pancreatic malignancy in patients with branch duct intraductal papillary mucinous neoplasm in a referral center. Gastroenterology. 2017;153:1284-1294.e1.PubMedCrossRef
42.
go back to reference He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg. 2013;216:657–65; discussion 665–7. He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg. 2013;216:657–65; discussion 665–7.
43.
go back to reference Marchegiani G, Mino-Kenudson M, Ferrone CR, et al. Patterns of recurrence after resection of IPMN: Who, when, and how? Ann Surg. 2015;262:1108–1114.PubMedCrossRef Marchegiani G, Mino-Kenudson M, Ferrone CR, et al. Patterns of recurrence after resection of IPMN: Who, when, and how? Ann Surg. 2015;262:1108–1114.PubMedCrossRef
44.
go back to reference Sauvanet A, Gaujoux S, Blanc B, et al. Parenchyma-sparing pancreatectomy for presumed noninvasive intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2014;260:364–371.PubMedCrossRef Sauvanet A, Gaujoux S, Blanc B, et al. Parenchyma-sparing pancreatectomy for presumed noninvasive intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2014;260:364–371.PubMedCrossRef
45.
go back to reference Lekkerkerker SJ, Besselink MG, Busch OR, et al. Comparing 3 guidelines on the management of surgically removed pancreatic cysts with regard to pathological outcome. Gastrointest Endosc. 2017;85:1025–1031.PubMedCrossRef Lekkerkerker SJ, Besselink MG, Busch OR, et al. Comparing 3 guidelines on the management of surgically removed pancreatic cysts with regard to pathological outcome. Gastrointest Endosc. 2017;85:1025–1031.PubMedCrossRef
46.
go back to reference Fong ZV, Sekigami Y, Qadan M, et al. Assessment of the long-term impact of pancreatoduodenectomy on health-related quality of life using the EORTC QLQ-PAN26 module. Ann Surg Oncol. 2021;28:4216–4224.PubMedCrossRef Fong ZV, Sekigami Y, Qadan M, et al. Assessment of the long-term impact of pancreatoduodenectomy on health-related quality of life using the EORTC QLQ-PAN26 module. Ann Surg Oncol. 2021;28:4216–4224.PubMedCrossRef
47.
go back to reference Lim P-W, Dinh KH, Sullivan M, et al. Thirty-day outcomes underestimate endocrine and exocrine insufficiency after pancreatic resection. HPB . 2016;18:360–366.PubMedPubMedCentralCrossRef Lim P-W, Dinh KH, Sullivan M, et al. Thirty-day outcomes underestimate endocrine and exocrine insufficiency after pancreatic resection. HPB . 2016;18:360–366.PubMedPubMedCentralCrossRef
48.
go back to reference Puri PM, Watkins AA, Kent TS, et al. Decision-making for the management of cystic lesions of the pancreas: How satisfied are patients with surgery? J Gastrointest Surg. 2018;22:88–97.PubMedCrossRef Puri PM, Watkins AA, Kent TS, et al. Decision-making for the management of cystic lesions of the pancreas: How satisfied are patients with surgery? J Gastrointest Surg. 2018;22:88–97.PubMedCrossRef
49.
go back to reference Wilson GC, Maithel SK, Bentrem D, et al. Are the current guidelines for the surgical management of intraductal papillary mucinous neoplasms of the pancreas adequate? A multi-institutional study. J Am Coll Surg. 2017;224:461–469.PubMedCrossRef Wilson GC, Maithel SK, Bentrem D, et al. Are the current guidelines for the surgical management of intraductal papillary mucinous neoplasms of the pancreas adequate? A multi-institutional study. J Am Coll Surg. 2017;224:461–469.PubMedCrossRef
50.
go back to reference Ohtsuka T, Kono H, Nagayoshi Y, et al. An increase in the number of predictive factors augments the likelihood of malignancy in branch duct intraductal papillary mucinous neoplasm of the pancreas. Surgery. 2012;151:76–83.PubMedCrossRef Ohtsuka T, Kono H, Nagayoshi Y, et al. An increase in the number of predictive factors augments the likelihood of malignancy in branch duct intraductal papillary mucinous neoplasm of the pancreas. Surgery. 2012;151:76–83.PubMedCrossRef
51.
go back to reference Zelga P, Hernandez-Barco YG, Qadan M, et al. Number of worrisome features and risk of malignancy in intraductal papillary mucinous neoplasm. J Am Coll Surg. 2022;234:1021–1030.PubMedCrossRef Zelga P, Hernandez-Barco YG, Qadan M, et al. Number of worrisome features and risk of malignancy in intraductal papillary mucinous neoplasm. J Am Coll Surg. 2022;234:1021–1030.PubMedCrossRef
52.
go back to reference Paiella S, De Pastena M, Faustini F, et al. Central pancreatectomy for benign or low-grade malignant pancreatic lesions - A single-center retrospective analysis of 116 cases. Eur J Surg Oncol. 2019;45:788–792.PubMedCrossRef Paiella S, De Pastena M, Faustini F, et al. Central pancreatectomy for benign or low-grade malignant pancreatic lesions - A single-center retrospective analysis of 116 cases. Eur J Surg Oncol. 2019;45:788–792.PubMedCrossRef
53.
go back to reference Couvelard A, Sauvanet A, Kianmanesh R, et al. Frozen sectioning of the pancreatic cut surface during resection of intraductal papillary mucinous neoplasms of the pancreas is useful and reliable. Ann Surg. 2005;242:774–780.PubMedPubMedCentralCrossRef Couvelard A, Sauvanet A, Kianmanesh R, et al. Frozen sectioning of the pancreatic cut surface during resection of intraductal papillary mucinous neoplasms of the pancreas is useful and reliable. Ann Surg. 2005;242:774–780.PubMedPubMedCentralCrossRef
54.
go back to reference Kang MJ, Jang J-Y, Kim SJ, et al. Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol. 2011;9:87–93.PubMedCrossRef Kang MJ, Jang J-Y, Kim SJ, et al. Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol. 2011;9:87–93.PubMedCrossRef
55.
go back to reference Rautou P-E, Lévy P, Vullierme M-P, et al. Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study. Clin Gastroenterol Hepatol. 2008;6:807–814.PubMedCrossRef Rautou P-E, Lévy P, Vullierme M-P, et al. Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study. Clin Gastroenterol Hepatol. 2008;6:807–814.PubMedCrossRef
56.
go back to reference Ciprani D, Weniger M, Qadan M, et al. Risk of malignancy in small pancreatic cysts decreases over time. Pancreatology. 2020;20:1213–1217.PubMedCrossRef Ciprani D, Weniger M, Qadan M, et al. Risk of malignancy in small pancreatic cysts decreases over time. Pancreatology. 2020;20:1213–1217.PubMedCrossRef
57.
go back to reference Johansson K, Kaprio T, Nieminen H, et al. A retrospective study of intraductal papillary neoplasia of the pancreas (IPMN) under surveillance. Scand J Surg. 2022;111:14574969221076792.PubMedCrossRef Johansson K, Kaprio T, Nieminen H, et al. A retrospective study of intraductal papillary neoplasia of the pancreas (IPMN) under surveillance. Scand J Surg. 2022;111:14574969221076792.PubMedCrossRef
58.
go back to reference Yang KS, Ciprani D, O’Shea A, et al. Extracellular vesicle analysis allows for identification of invasive IPMN. Gastroenterology. 2021;160:1345-1358.e11.PubMedCrossRef Yang KS, Ciprani D, O’Shea A, et al. Extracellular vesicle analysis allows for identification of invasive IPMN. Gastroenterology. 2021;160:1345-1358.e11.PubMedCrossRef
Metadata
Title
A Clinical Guide to the Management of Intraductal Papillary Mucinous Neoplasms: the Need for a More Graded Approach in Clinical Decision-making
Authors
Zhi Ven Fong
Yasmin G. Hernandez-Barco
Carlos Fernández-del Castillo
Publication date
26-07-2023
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 9/2023
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-022-05536-1

Other articles of this Issue 9/2023

Journal of Gastrointestinal Surgery 9/2023 Go to the issue
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare